Highest-materiality recent filing
Talphera reports Q4 net loss $3.8M; NEPHRO CRRT study 50% enrolled, all 12 sites active
Cash and investments $20.4M at Dec 31, 2025; net loss $3.8M ($0.06 per share) vs $1.9M ($0.07) in Q4 2024.
Talphera closes $4.1M third tranche of private placement, issuing shares and warrants
Third closing on March 13, 2026: 639,931 shares at $0.586/share and pre-funded warrants for 6,399,316 shares at $0.585 each.
Talphera receives Nasdaq bid price deficiency notice; 180 days to regain compliance
Received Nasdaq notice on March 11, 2026 for non-compliance with minimum bid price of $1.00 per share.
Talphera Q3 net loss $4.4M; cash $21.3M; Niyad study on track for H1 2026
Net loss $4.4M ($0.11/sh) vs $3.4M ($0.13/sh) in Q3 2024.
Talphera raises ~$1.6M in final private placement tranches; regains Nasdaq compliance
Issued 1,023,890 shares at $0.586/share and pre-funded warrants for 1,706,484 shares at $0.585/warrant.
Talphera raises ~$17M in private placement with CorMedix; second closing tied to NEPHRO CRRT
Issued 25,036,360 shares at $0.55/share and pre-funded warrants for 5,845,455 shares; gross proceeds ~$17M.
Talphera Q2 net loss $3.5M ($0.10/sh); NEPHRO study enrollment accelerates
15 patients enrolled in NEPHRO registrational study; on track for completion by end of 2025, PMA submission Q1 2026.
Talphera gets 180-day extension to regain Nasdaq $1.00 bid price compliance through Dec 1, 2025
Received Nasdaq notice granting second 180-day compliance period until December 1, 2025 for minimum bid price requirement.
Talphera Q1 2025 net loss narrows to $0.10/share; NEPHRO study reduced to 70 patients
Net loss from continuing ops $2.7M vs $4.0M YoY; diluted EPS loss $0.10 vs $0.16.
Gross proceeds of ~$4.9M from first closing: 3,405,118 shares and pre-funded warrants for 4,999,316 shares at $0.586/share.
Talphera reports Q4 2024 net loss $1.9M; FDA cuts NEPHRO study size to 70 patients
FDA agreed to reduce NEPHRO CRRT study from 166 to 70 patients; study completion targeted by end of 2025.
Talphera receives Nasdaq notice for non-compliance with $1.00 minimum bid price
Received Nasdaq notice on Dec 6, 2024 for failure to maintain minimum bid price of $1.00 for 30 consecutive business days.
Talphera receives Nasdaq deficiency notice for stockholders' equity below $10M
Stockholders' equity as of Sept 30, 2024 was $9.641M, below Nasdaq's $10M minimum for Global Market.
Talphera Q3 net loss widens to $3.4M; NEPHRO CRRT study enrollment underway
Net loss $3.4M ($0.13/share) vs $1.4M ($0.08) in Q3 2023; cash and investments $11.1M.
Talphera reports Q1 2024 net loss $4.0M; NEPHRO study enrollment delayed, guidance revised
Net loss from continuing ops $4.0M vs income $0.1M in Q1 2023; basic EPS -$0.16.
Talphera Q4 net loss $4.5M; cash $9.4M; Niyad study enrollment imminent; $26M committed
Net loss from continuing ops of $4.5M ($0.25/sh) vs $5.9M ($1.00/sh) in Q4 2022; revenues $0.3M.
Upon Dr. Palmer’s retirement, Dr. Shakil Aslam, currently the Company’s Chief Development Officer, will assume the position of the Company’s Chief Medical Officer.
On August 12, 2024, Pamela P. Palmer, MD, PhD, the Company’s Chief Medical Officer and co-founder, notified the Company that she plans to retire and resign from the Company effective October 1, 2024.
On February 26, 2024, Richard Afable, M.D. and Howard B. Rosen resigned as members of the board of directors of Talphera, Inc. (the "Company"), and any and all committees thereof, effective immediately.
On February 26, 2024, Richard Afable, M.D. and Howard B. Rosen resigned as members of the board of directors of Talphera, Inc. (the "Company"), and any and all committees thereof, effective immediately.
On February 28, 2024, Pamela P. Palmer, M.D., Ph.D. resigned as a member of the Company's board of directors effective immediately.
Max materiality 0.85 · Median 0.65 · Most common event earnings